CDK2 and cancer: The use of peptide aptamers could be effective for the disruption of specific targets [34], and multiple peptide aptamers have been explored to inhibit target-specific proteins, such as cyclin-dependent kinase 2 (CDK2) [35], Nr13 protein [36], and mutant p53 [37], thereby inhibiting cancer progression.